Ask the Expert: What Happens If I Become Resistant to Ibrutinib?

Published on

Topics include: Treatments and Understanding

Which additional CLL treatment options are available for patients who develop resistance to ibrutinib (Imbruvica)? In this “Ask the Expert” session, Dr. Michael Keating, a leading CLL expert from The University of Texas MD Anderson Cancer Center, explains alternative inhibitor approaches if a patient becomes resistant. Dr. Keating also explains the role of monoclonal antibodies.

This Ask the Expert series is a Patient Empowerment Network program produced by Patient Power.   We thank AbbVie and Genentech for their support.

View more programs featuring and

Produced in association with

Related Programs

Could Antibodies and Inhibitors Be Combined to Improve Response Rates?

Dr. Philip Thompson of MD Anderson Cancer Center discusses safety and efficacy of combined BTK inhibitor therapies in current studies.


Do You Have to Take Inhibitor Treatments Forever?

From our Ask the Expert series, Dr. Michael Keating of MD Anderson Cancer Center answers a common CLL question: “Do inhibitor treatments have to be a lifelong medicine?”


Join Our Community Register for Events Read Our Latest Blog

Page last updated on October 16, 2017